letrozole

P2, N=60, Recruiting, University of Texas Southwestern Medical Center | Trial primary completion date: Apr 2026 --> Apr 2027

P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132

Obesity was associated with lower ORR with letrozole alone, whereas this association was not observed in patients treated with taselisib.

P1, N=15, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting

Six cycles of systemic chemotherapy with epirubicin and cyclophosphamide at three-week intervals were administered, followed by endocrine therapy with letrozole. Almost four years later, palbociclib became available and it was added to the patient's treatment...As this is a single-case clinical observation, any conclusions have limited generalizability. Given the rarity of primary metastatic ulcerative breast cancer there are no specific evidence-based treatment guidelines available and published studies have high heterogeneity and low level of evidence, necessitating multidisciplinary approach on a case-by-case basis.

P1/2, N=80, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

The present study evaluated berberine-gallic acid (BBR-GAL) and berberine-gentisic acid (BBR-GEN) using an integrated in silico and in vivo approach in a letrozole-induced PCOS mouse model...By restoring hepatic insulin signaling through modulation of the adenosine monophosphate-activated protein kinase-insulin receptor substrate-1/phosphatidylinositol 3-kinase/protein kinase B axis and attenuating ovarian inflammation, these formulations provide mechanistic validation for improved therapeutic efficacy. These findings indicate that crystal-engineered BBR could be a useful approach in improving the endocrine-metabolic phenotypes of preclinical PCOS.

Therefore, this study investigates the ameliorative effects of total flavonoids from Rubus chingii Hu (RHF) on HPO axis function and inflammatory response in a rat model of PCOS induced by letrozole...In ovarian tissue, RHF downregulated the protein and mRNA expression of NLRP3, caspase-1, the N-terminal fragment of gasdermin D (GSDMD-NT), IL-18, and IL-1β, and lowered the mRNA levels of IL-6 and TNF-α, thereby attenuating both systemic and local ovarian inflammatory responses. Taken together, these findings demonstrate that RHF confers protective effects in PCOS rats, which are associated with the amelioration of HPO axis function and suppression of inflammatory responses.

P1, N=33, Completed, BeOne Medicines | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Apr 2026

P=N/A, N=400, Completed, Sohag University

P3, N=1556, Suspended, Alliance for Clinical Trials in Oncology | N=1156 --> 1556

We investigated whether DHED could prevent side effects associated with the aromatase inhibitor letrozole in a primate model of aging...Here, we show that a brain-selective estrogen therapy administered orally via the prodrug DHED substantially increases estrogen levels in the marmoset brain without affecting the periphery and normalizes impairments in working memory, hippocampal neuronal excitability and sleep induced by aromatase inhibition. These findings in a translational primate model represent a significant advance for women's health by positioning DHED as a non-invasive, safe and efficient novel hormone therapy to improve quality of life of women with ER+ breast cancers.